Humanin and SHLP-2: The Lesser-Known Mitochondrial Peptides With Big Metabolic Implications

Your mitochondria do more than produce energy. They produce peptides — signalling molecules that circulate through your body and regulate metabolism, insulin sensitivity, inflammation, and aging. Two of the most clinically compelling examples are humanin and SHLP-2.

The humanin peptide metabolic benefits are well-documented in peer-reviewed literature: improved insulin sensitivity, protection of pancreatic beta cells, reduced oxidative stress, and measurable correlations with longevity. SHLP-2, its structural cousin, acts on hypothalamic neurons to suppress appetite and improve energy homeostasis. Both peptides decline with age — and that decline tracks with the very metabolic disorders that define modern chronic disease.

This is not fringe biology. It is published science from USC, Albert Einstein College of Medicine, and the journal Aging. Here is what the evidence actually shows.

What Are Mitochondrial-Derived Peptides?

Mitochondrial-derived peptides (MDPs) are a recently identified class of signalling molecules encoded directly within the mitochondrial genome. They are not synthesised by nuclear DNA. They are produced inside the mitochondria themselves, released into circulation, and act on distant tissues.

Humanin was the first MDP discovered, identified in 2001 from a cDNA library derived from the occipital cortex of an Alzheimer's patient. Researchers initially flagged it for its neuroprotective properties. It took nearly a decade before its metabolic role came into focus.

Since then, researchers at the USC Leonard Davis School of Gerontology have identified six additional peptides in the same mitochondrial 16S rRNA region as humanin. These were named small humanin-like peptides — SHLPs 1 through 6. Of these, SHLP-2 has emerged as the most metabolically active.

The broader MDP family now includes:

• Humanin (HN) — neuroprotective, insulin-sensitising, anti-apoptotic
• SHLP-2 — hypothalamic energy regulation, appetite suppression, thermogenesis
• SHLP-3 — reduced reactive oxygen species (ROS), improved mitochondrial metabolism
• MOTS-c — AMPK activation, glucose uptake, physical capacity

Each of these peptides performs a different function. Together, they constitute what researchers are now calling a mitochondrial signalling system — one that declines with age and, in doing so, may accelerate the metabolic deterioration we associate with getting older.

Humanin Peptide Metabolic Benefits: What the Research Shows

The humanin peptide metabolic benefits span several interconnected pathways. Here is the evidence, by mechanism.

1. Humanin Improves Insulin Sensitivity

This is the most clinically significant finding for metabolic patients.

Dr. Nir Barzilai's team at Albert Einstein College of Medicine demonstrated that a small infusion of humanin was among the most potent regulators of insulin metabolism they had ever observed in their research. In Zucker diabetic fatty rats, central infusion of humanin — and its more potent analogue HNG — significantly improved overall insulin sensitivity and reduced blood glucose levels.

The mechanism involves hypothalamic STAT-3 signalling. When humanin activates STAT-3 in the hypothalamus, it modulates peripheral glucose metabolism through central insulin-sensitising pathways. This is a brain-body feedback loop — humanin tells the brain to improve how the body handles glucose.

Separately, animal studies showed that humanin analogues increased insulin secretion in response to elevated blood glucose. The effect was confirmed in both normal and diabetic islets from mouse pancreata, and was directly linked to glucose metabolism within the beta cells themselves. When that glucose metabolism was blocked, humanin lost its insulin-secreting effect — establishing a clear mechanistic dependency.

For patients with insulin resistance or prediabetes, this mechanistic data is directly relevant.

2. Humanin Protects Pancreatic Beta Cells

Beta cells are the insulin-producing factories of the pancreas. In type 2 diabetes, beta cell function declines progressively. Humanin protects them through two parallel mechanisms:

1. Anti-apoptotic signalling — Humanin suppresses programmed cell death by antagonising pro-apoptotic factors including Bax and IGFBP-3. This protects beta cells from stress-induced destruction.
2. Glucose-stimulated insulin secretion — Beyond protection, humanin actively enhances insulin secretion when glucose levels rise, suggesting a role in real-time glycaemic regulation.

In NOD mouse models of type 1 diabetes, humanin also delayed disease onset — a finding with implications for autoimmune beta cell destruction.

3. Humanin Declines With Age

This is where the clinical picture becomes sobering.

Humanin levels naturally decline with age — in both humans and animal models. The decline is consistent and measurable in circulating blood levels. Critically, children of centenarians have significantly higher humanin levels than age-matched controls. This suggests that elevated baseline humanin — or a slower rate of humanin decline — may be a heritable feature of longevity biology.

The inverse is also true. Patients with Alzheimer's disease show reduced humanin levels. Patients with metabolic conditions including type 2 diabetes have lower circulating humanin relative to healthy controls.

Humanin is not a static background molecule. It is a dynamic indicator of metabolic and mitochondrial health — and its trajectory with age mirrors the trajectory of metabolic decline.

4. Humanin Reduces Inflammation and Oxidative Stress

Beyond glucose metabolism, humanin modulates inflammatory markers and reduces reactive oxygen species (ROS). This matters because chronic low-grade inflammation — driven by oxidative stress — underpins most metabolic disease progression, from fatty liver to cardiovascular dysfunction to metabolic syndrome.

In animal models of overexpressed humanin, researchers observed improved glucose regulation, better lipid metabolism, and a measurable reduction in oxidative stress — all without pharmacological intervention. The mechanism was internal: the humanin system itself doing the regulatory work.

SHLP-2: The Mitochondrial Peptide for Energy Homeostasis

SHLP-2 (small humanin-like peptide 2) shares humanin's origin — the MT-RNR2 gene in mitochondrial DNA — but it operates through distinct mechanisms with distinct metabolic targets.

SHLP-2 and Insulin Sensitivity: Central and Peripheral Action

A foundational 2016 study from USC, published in the journal Aging, established the metabolic profile of SHLP-2 through hyperinsulinemic-euglycemic clamp studies. The findings were clear:

• Intracerebrally infused SHLP-2 increased glucose uptake in peripheral tissues
• SHLP-2 suppressed hepatic glucose production — reducing the liver's contribution to blood sugar elevation
• These effects operated both centrally (via the brain) and peripherally (via systemic action)

This dual-site insulin-sensitising effect is notable. Most interventions for insulin resistance act through a single primary pathway. SHLP-2 appears to engage two simultaneously.

SHLP-2 Activates POMC Neurons to Suppress Appetite

A 2023 Nature Communications study added critical detail to the SHLP-2 picture.

Researchers showed that both systemic and intracerebroventricular administration of SHLP-2 protected male mice from high-fat diet-induced obesity. The mechanism involved the activation of pro-opiomelanocortin (POMC) neurons in the arcuate nucleus of the hypothalamus — one of the brain's primary appetite-regulation centres.

POMC neuron activation by SHLP-2 produced two downstream effects:

1. Suppression of food intake — reduced caloric consumption without pharmacological appetite-suppressing agents
2. Promotion of thermogenesis — increased metabolic rate through heat production

Through high-throughput structural screening, the same researchers identified that SHLP-2 binds to and activates chemokine receptor 7 (CXCR7) — its functional receptor. This is a significant finding. Knowing the receptor enables drug development, targeted delivery strategies, and mechanistic research with far greater precision.

SHLP-2 Also Declines With Age

Like humanin, circulating SHLP-2 levels decline with age. The same USC study documented decreased serum SHLP-2 in both diabetic and obese patients — and in animal models of diabetes and obesity including db/db and ob/ob mice.

The pattern is consistent: SHLP-2 is lower in the populations with the most metabolic dysfunction. Whether that decline is a cause or a consequence — or both — is still being investigated. But the correlation is directionally clear.

Humanin and SHLP-2: Side-by-Side Comparison

Why These Peptides Matter for Aging and Longevity Patients

The patients most likely to benefit from understanding humanin and SHLP-2 are those engaged in evidence-based longevity protocols — not patients seeking a quick fix, but those who want to understand the biology of metabolic decline before it becomes clinical disease.

Here is the core argument:

• Humanin and SHLP-2 are endogenous regulators — your body makes them, uses them, and loses the ability to produce them adequately as you age
• Their decline tracks with insulin resistance, metabolic syndrome, obesity, and neurodegeneration — the four major phenotypes of metabolic aging
• Interventions that slow mitochondrial decline — caloric restriction, exercise, specific peptide protocols — appear to preserve or partially restore MDP levels
• Centenarian research suggests that high baseline humanin is a feature of biological longevity, not just a correlate

If you are managing insulin resistance, working through weight loss resistance, or navigating metabolic syndrome, these peptides sit at the biological junction between what is happening in your cells and what you are experiencing in your body.

Understanding them is not optional if you want to address root causes — it is foundational.

Where Humanin and SHLP-2 Fit in a Broader Peptide Protocol

Humanin and SHLP-2 are not yet available as pharmaceutical-grade clinical interventions in the way that GLP-1 receptor agonists or tesamorelin are. They are at the translational research stage — meaning the mechanistic evidence is robust, but randomised clinical trials in humans are still limited.

That said, their biology is increasingly informing how clinicians think about the mitochondrial axis of metabolic health — and how other interventions, including growth hormone peptides, MOTS-c research, and GLP-1 therapies, can be layered into a coherent protocol.

Specifically:

• Patients using CJC-1295/ipamorelin stacks to improve body composition are activating growth hormone pathways that intersect with IGF-1 — the same axis that humanin interacts with via IGFBP-3 antagonism
• Patients using GLP-1 agonists for weight management are activating hypothalamic POMC neurons — the same neurons that SHLP-2 targets
• Patients pursuing longevity-focused lab panels may soon see MDP biomarkers integrated into standard metabolic assessments as the clinical translation of this research matures

The peptide landscape is converging. Humanin and SHLP-2 are not isolated curiosities — they are core members of a mitochondrial signalling family that will likely reshape how metabolic aging is both assessed and treated.

What This Means for Your Health Right Now

If you are not yet working with a clinician on metabolic root causes, the research above is a strong argument to start. Here is what is actionable today:

1. Assess your metabolic baseline. Fasting insulin, HbA1c, IGF-1, CMP, lipid panel. These biomarkers sit in the same biological territory as humanin function. You cannot optimise what you have not measured. Meto's Comprehensive Metabolic Panel is a direct starting point.
2. Address insulin resistance early. The decline in humanin and SHLP-2 with age is accelerated by insulin resistance. Reversing insulin resistance through medical-grade interventions — including evidence-based peptide protocols — may slow MDP decline at its source.
3. Do not wait for clinical symptoms. Humanin decline is measurable before metabolic disease becomes diagnosable. The most effective interventions happen in the window before dysfunction becomes irreversible.
4. Work with a specialist who understands the biology. The intersection of mitochondrial peptide biology, insulin signalling, and metabolic aging is not standard primary care territory. It is the domain of metabolic medicine specialists.

If your goal is to age well — not just avoid disease, but maintain function, body composition, cognitive clarity, and metabolic flexibility — then understanding what your mitochondria are signalling matters more than any single supplement or diet.

Conclusion

Humanin and SHLP-2 represent a new class of biology. They are not injected pharmaceuticals or synthetic compounds. They are peptides your own mitochondria produce — signals that tell the rest of your body how to manage glucose, protect cells, regulate appetite, and mount a defence against oxidative damage.

Their decline is not inevitable destiny. It is a measurable biological event with root causes that can be identified and, increasingly, addressed.

The humanin peptide metabolic benefits — insulin sensitisation, beta cell protection, reduced inflammation, longevity correlation — are among the most compelling findings in translational metabolic medicine. SHLP-2's role in energy homeostasis and hypothalamic appetite regulation adds a second, distinct channel through which mitochondrial biology shapes your metabolic fate.

The science is still maturing. But the direction is clear: your mitochondria are not just your energy source. They are your metabolic command centre — and the signals they send are worth paying close attention to.

Explore the full spectrum of evidence-based metabolic peptides at Meto. Start with your metabolic assessment and connect with a clinician who can match the science to your biology.

Frequently Asked Questions

What is humanin and how does it affect metabolism?

Humanin is a 24-amino-acid peptide encoded in the mitochondrial genome. It improves insulin sensitivity through hypothalamic STAT-3 signalling, protects pancreatic beta cells from stress-induced death, and reduces reactive oxygen species. Its metabolic effects have been demonstrated in multiple rodent models of diabetes and obesity, and circulating humanin levels are lower in patients with metabolic disease than in healthy controls.

Does humanin decline with age, and why does that matter?

Yes. Circulating humanin levels decline consistently with age in both humans and animal models. Centenarian studies show that children of long-lived individuals maintain higher humanin levels than age-matched controls — suggesting that a higher baseline, or a slower rate of decline, may be a heritable longevity feature. The decline matters because it tracks closely with the onset of insulin resistance, cognitive decline, and other age-related metabolic disorders.

What is SHLP-2, and how is it different from humanin?

SHLP-2 (small humanin-like peptide 2) is a 38-amino-acid mitochondrial peptide encoded in the same mitochondrial gene region as humanin. While humanin primarily acts on insulin signalling and beta cell survival, SHLP-2 works through the hypothalamic POMC neuron pathway to suppress appetite, promote thermogenesis, and improve energy homeostasis. A 2023 Nature Communications study identified CXCR7 as its functional receptor and showed protection against high-fat diet-induced obesity in animal models.

Are humanin and SHLP-2 available as clinical peptide therapies?

Not yet — at least not in the form of FDA-approved pharmaceutical interventions. Both peptides are in the translational research phase, meaning the preclinical and mechanistic evidence is strong but large-scale randomised controlled trials in humans are still limited. They are not currently prescribed clinically in the same way that GLP-1 agonists or growth hormone peptides are. Clinicians working in longevity medicine are monitoring the literature closely, and some compounding pharmacies offer analogues, though patients should approach these with appropriate caution and medical supervision.

How do I know if my mitochondrial peptide levels are declining?

There is no standardised clinical blood test for circulating humanin or SHLP-2 levels in routine metabolic panels — yet. However, proxy biomarkers — fasting insulin, HOMA-IR, HbA1c, IGF-1, inflammatory markers — reflect the same biological terrain these peptides operate in. Consistently worsening metabolic labs in the absence of obvious lifestyle causes may be an indirect signal of mitochondrial signalling decline. A structured metabolic assessment with a specialist is the most productive starting point.

Can exercise or lifestyle changes influence humanin and SHLP-2 levels?

The research is early but directionally positive. Humanin appears to promote beneficial metabolic adaptations following exercise, and some evidence suggests that regular physical activity is associated with better-preserved mitochondrial function — which would logically support MDP production. Caloric restriction, which extends lifespan in multiple animal models, also appears to preserve mitochondrial integrity. These are not guarantees, but they are consistent with the broader biology: mitochondrial health supports MDP production, and lifestyle decisions that protect mitochondria are likely to preserve these signalling peptides for longer.